These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27203384)

  • 1. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
    Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R
    Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
    Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
    PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
    Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
    Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
    Saraswati S; Kumar S; Alhaider AA
    Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
    Niu G; Sun L; Pei Y; Wang D
    Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
    Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
    Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.